Trial · NCT07897708
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Serious Adverse Events (SAEs) | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Laboratory Abnormalities | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Vital Signs Abnormalities | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings | From first dose through approximately 28 to 35 days after the last dose | |
| Primary | Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS) | From first dose through approximately 28 to 35 days after the last dose | |
| Secondary | Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) | Part A only: Up to Day 5 | |
| Secondary | Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau) | Part B only: Up to Day 17 | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) | Part A: Up to Day 5 Part B: Up to Day 17 | |
| Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) | Part A: Up to Day 5 Part B: Up to Day 17 | |
| Secondary | Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) if data permit | Part A only: Up to Day 5 | |
| Secondary | Plasma Decay Half-life (t1/2) if data permit | Part A only: Up to Day 5 | |
| Secondary | Cerebrospinal Fluid (CSF) Concentration of PF-08161842 | Part A: At day 2 post dose Part B: At day 15 post dose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07897708/registered